A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity

被引：17

作者：

Porter, JB

Faherty, A

Stallibrass, L

Brookman, L

Hassan, I

Howes, C

机构：

[1] UCL, Dept Haematol, London WC1E 6BT, England

[2] Novartis Pharmaceut, Horsham, W Sussex, England

来源：

COOLEYS ANEMIA: SEVENTH SYMPOSIUM | 1998年 / 850卷

关键词：

D O I：

10.1111/j.1749-6632.1998.tb10528.x

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

引用

页码：483 / 487

页数：5

共 7 条

[1] OCULAR CHANGES IN PATIENTS UNDERGOING LONG-TERM DESFERRIOXAMINE TREATMENT
ARDEN, GB
WONKE, B
KENNEDY, C
HUEHNS, ER
[J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1984, 68 (12) : 873 - 877
[2] A PREDICTOR FOR SIDE-EFFECTS IN PATIENTS WITH ALZHEIMERS-DISEASE TREATED WITH DEFEROXAMINE MESYLATE
KRUCK, TPA
FISHER, EA
MCLACHLAN, DRC
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (01) : 30 - 37
[3] LEE P, 1993, DRUG METAB DISPOS, V21, P640
[4] OLIVIERI NF, 1992, AM J PEDIAT HEMATOL, V14, P48
[5] Porter J B, 1989, Baillieres Clin Haematol, V2, P459, DOI 10.1016/S0950-3536(89)80027-7
[6] DESFERRIOXAMINE OTOTOXICITY - EVALUATION OF RISK-FACTORS IN THALASSEMIC PATIENTS AND GUIDELINES FOR SAFE DOSAGE
PORTER, JB
JASWON, MS
HUEHNS, ER
EAST, CA
HAZELL, JWP
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (03) : 403 - 409
[7] PORTER JB, 1992, 24 INT SOC HAEM 1992, P184